We are proud to welcome Dr. Nick France, MD, MRCPCH, to the Board of Directors at the Foundation for Angelman Syndrome Therapeutics.
Dr. France is a physician-scientist and seasoned leader in rare disease drug development, with a career that spans every stage of the biopharmaceutical landscape, from early-stage biotech to global pharmaceutical companies. He currently serves as Vice President, Global Therapeutic Area Head for Neurology and Head of Genomic Medicines Development at Alexion, AstraZeneca Rare Disease.
Over the past two decades, Dr. France has helped advance therapies for both children and adults living with rare conditions. He has held leadership roles at organizations including ReCode Therapeutics, ESCAPE Bio, Roivant Sciences, CSL Behring, and GlaxoSmithKline, working across a wide range of therapeutic approaches, from small molecules to gene therapies.
Beyond clinical development, Dr. France has helped shape strategic direction at the highest levels, with experience in business development, fundraising, portfolio strategy, and the pursuit of new therapeutic opportunities.
He also serves as a scientific advisor to the INAD Cure Foundation, a parent-led organization focused on advancing treatments for an ultra-orphan neurodegenerative disease.
Dr. France brings not only deep scientific expertise, but also a personal commitment to driving progress in rare disease research. We are honored to have his insight and leadership as part of FAST’s mission to accelerate meaningful treatments for the Angelman syndrome community.
Want to learn more? Meet the full FAST Board of Directors.